| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
AGIO
Agios Pharma
|
Jun 16, 2026 | BUY |
Strong Buy
+73.2% avg upside
29 analysts
|
— | · |
|
INCY
Incyte
|
Jun 15, 2026 | BUY |
Strong Buy
+1.0% avg upside
47 analysts
|
$124.00
26.28% Upside
|
-2.9% |
|
DMRA
Damora Therapeutics
|
Jun 11, 2026 | BUY |
Strong Buy
+28.3% avg upside
19 analysts
|
— | · |
|
NUVL
Nuvalent
|
Jun 10, 2026 | HOLD |
Buy
-0.3% avg upside
21 analysts
|
$124.00
0.39% Upside
|
+0.0% |
|
CGEM
Cullinan Management
|
Jun 10, 2026 | BUY |
Strong Buy
+125.7% avg upside
15 analysts
|
— | +19.8% |
|
CRDF
Cardiff Oncology
|
Jun 04, 2026 | HOLD |
Strong Buy
+732.8% avg upside
18 analysts
|
— | · |
|
RVMD
Revolution Medicines
|
Jun 01, 2026 | BUY |
Strong Buy
-12.3% avg upside
32 analysts
|
— | -3.6% |
|
ACRV
Acrivon Therapeutics, Inc.
|
May 14, 2026 | BUY |
Strong Buy
+817.2% avg upside
13 analysts
|
— | -7.8% |
|
SANA
Sana Biotechnology
|
May 11, 2026 | BUY |
Strong Buy
+214.8% avg upside
14 analysts
|
— | -20.5% |
|
TBPH
Theravance Biopharma
|
May 08, 2026 | HOLD |
Buy
+12.2% avg upside
18 analysts
|
$15.00
9.58% Downside
|
-1.8% |
|
JANX
Janux Therapeutics Inc
|
May 08, 2026 | BUY |
Strong Buy
+217.1% avg upside
21 analysts
|
— | -0.2% |
|
NKTR
Nektar Therapeutics
|
May 08, 2026 | BUY |
Strong Buy
+16.5% avg upside
25 analysts
|
— | -25.6% |
|
PBYI
Puma Biotechnology
|
May 08, 2026 | HOLD |
Hold
+458.2% avg upside
11 analysts
|
$5.00
33.79% Downside
|
-8.5% |
|
GLUE
Monte Rosa Therapeutics
|
May 07, 2026 | BUY |
Strong Buy
+27.5% avg upside
14 analysts
|
— | -7.6% |
|
SRRK
Scholar Rock Holding
|
May 07, 2026 | BUY |
Strong Buy
+20.1% avg upside
23 analysts
|
— | +1.1% |
|
BDTX
Black Diamond Therapeutics
|
May 07, 2026 | BUY |
Strong Buy
+984.3% avg upside
12 analysts
|
— | +1.1% |
|
STTK
Shattuck Labs
|
May 07, 2026 | BUY |
Strong Buy
+369.1% avg upside
14 analysts
|
— | -30.8% |
|
KYMR
Kymera Therapeutics
|
May 05, 2026 | BUY |
Strong Buy
+8.9% avg upside
36 analysts
|
— | +8.7% |
|
XLO
Xilio Therapeutics
|
Nov 13, 2025 | BUY |
Strong Buy
+95.7% avg upside
7 analysts
|
— | -21.9% |
|
ADAPY
Adaptimmune Therapeutics
|
Nov 14, 2024 | BUY |
Hold
+5712.5% avg upside
10 analysts
|
— | · |
|
XFOR
X4 Pharmaceuticals
|
Jan 12, 2024 | HOLD |
Strong Buy
+491.4% avg upside
15 analysts
|
— | -30.5% |
|
DNTH
Dianthus Therapeutics
|
Jan 26, 2023 | HOLD |
Strong Buy
+8.8% avg upside
29 analysts
|
— | +154.0% |
|
ODTC
Odonate
|
Mar 22, 2021 | HOLD |
Buy
-99.9% avg upside
3 analysts
|
— | · |
|
ELTX
Elicio Therapeutics
|
Mar 02, 2021 | BUY |
Buy
+393.5% avg upside
11 analysts
|
— | -90.5% |
|
ALLO
Allogene Therapeutics
|
Aug 05, 2020 | BUY |
Strong Buy
+662.1% avg upside
28 analysts
|
— | -38.3% |
|
COGT
Cogent Biosciences
|
Feb 26, 2019 | HOLD |
Strong Buy
+7.1% avg upside
26 analysts
|
— | -84.0% |
|
LLY
Eli Lilly & Co
|
Jan 07, 2019 | HOLD |
Strong Buy
-10.5% avg upside
47 analysts
|
— | +17.5% |
|
ONC
BeOne Medicines
|
Dec 04, 2018 | BUY |
Strong Buy
+28.4% avg upside
28 analysts
|
— | +30.8% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.